HealthcareServices

Chronic Pulmonary Hypertension Treatment Market Forecast: What to Expect by 2029

November 27, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Chronic Pulmonary Hypertension Treatment Market Between 2025 And 2029?

The chronic pulmonary hypertension treatment market has experienced robust expansion in recent years. This market is projected to expand from $6.82 billion in 2024 to $7.19 billion in 2025, at a compound annual growth rate (CAGR) of 5.5%. The historical growth of this market can be attributed to factors such as the increasing prevalence of chronic pulmonary hypertension, a rise in drug approvals, favorable reimbursement policies, rising healthcare expenditure, and an aging population.

The chronic pulmonary hypertension treatment market is projected to experience robust expansion over the coming years. This market is anticipated to reach $8.89 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 5.4%. Factors contributing to this projected growth include a rising need for effective therapies, increased financial commitments, greater government backing for drug creation, an escalating desire for sophisticated treatments, enhanced public understanding, and a higher occurrence of chronic brain injuries. Key developments expected during this period involve the creation of novel drugs and treatments, technological progress, partnerships between pharmaceutical firms, research centers, and healthcare providers, discovery of new molecular targets, investments from governmental bodies and healthcare entities, and the introduction of innovative therapies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21148&type=smp

What Are The Key Drivers Of Growth In The Chronic Pulmonary Hypertension Treatment Market?

The significant prevalence of cardiovascular diseases is projected to fuel the expansion of the chronic pulmonary hypertension treatment market going forward. Cardiovascular diseases encompass various heart and blood vessel disorders, including conditions such as coronary artery disease, heart failure, and stroke. Their substantial impact is attributed to risk factors like unhealthy diets, physical inactivity, tobacco use, excessive alcohol consumption, obesity, hypertension, diabetes, and aging populations. Treatment for chronic pulmonary hypertension aids cardiovascular health by decreasing pulmonary artery pressure, improving cardiac function, and diminishing the likelihood of heart failure and associated complications. For instance, in December 2023, according to the Australian Institute of Health and Welfare, an Australia-based government agency, there were 14,100 doctor-certified deaths attributed to coronary heart disease (CHD) in 2021, increasing to 14,900 in 2022. Consequently, the widespread burden of cardiovascular diseases is a key factor propelling the growth of the chronic pulmonary hypertension treatment market.

How Is The Chronic Pulmonary Hypertension Treatment Market Classified Into Different Segments?

The chronic pulmonary hypertension treatmentmarket covered in this report is segmented –

1) By Drug Type: Endothelin Receptor Antagonists; Phosphodiesterase (PDE-5) Inhibitors; Prostacyclin Analogs; Soluble Guanylate Cyclase (SGC) Stimulators

2) By Route Of Administration: Oral; Intravenous Or Subcutaneous; Inhalational

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Endothelin Receptor Antagonists: Bosentan; Ambrisentan; Macitentan

2) By Phosphodiesterase (PDE-5) Inhibitors: Sildenafil; Tadalafil; Vardenafil

3) By Prostacyclin Analogs: Epoprostenol; Treprostinil; Iloprost

4) By Soluble Guanylate Cyclase (SGC) Stimulators: Riociguat

How Are Trends Influencing The Chronic Pulmonary Hypertension Treatment Market?

Leading firms within the chronic pulmonary hypertension treatment market are concentrating on novel approaches, like subcutaneous injection, to boost patient adherence, increase ease of use, and offer more precise therapeutic choices. This method of injection administers medication continuously beneath the skin, aiding in the reduction of pulmonary artery pressure and enhancing blood flow for individuals with pulmonary hypertension. An example of this is the March 2024 announcement by Merck & Co Inc., a pharmaceutical company based in the US, regarding the U.S. Food and Drug Administration (FDA) approval of Winrevair (sotatercept-csrk), which represents a notable step forward in treating pulmonary arterial hypertension (PAH). This cutting-edge therapy presents distinct advantages, setting it apart as a pioneering solution for PAH. Evidence from clinical trials indicates that Winrevair enhances WHO functional class in 29% of patients, in contrast to 14% observed in the placebo group, resulting in a general improvement in their quality of life.

Who Are The Major Companies Operating In The Chronic Pulmonary Hypertension Treatment Market?

Major companies operating in the chronic pulmonary hypertension treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi SA, AstraZeneca PLC, Novartis AG, GSK (GlaxoSmithKline), Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., Insmed, Cereno Scientific, Roivant Sciences, LGM Pharma, Liquidia Technologies

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/chronic-pulmonary-hypertension-treatment-global-market-report

Which Geographies Are Emerging As Strong Markets For The Chronic Pulmonary Hypertension Treatment Industry?

North America was the largest region in the chronic pulmonary hypertension treatment market in 2024. The regions covered in the chronic pulmonary hypertension treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Chronic Pulmonary Hypertension Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21148&type=smp

Browse Through More Reports Similar to the Global Chronic Pulmonary Hypertension Treatment Market 2025, By The Business Research Company

Chronic Disease Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Chronic Lower Back Pain Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Chronic Obstructive Pulmonary Disease Copd Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795